We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2020 - 31 Oct 2020
Virtual Venue
28 Oct 2020 - 30 Oct 2020
Virtual Venue

Hematological Biomarkers Predict Prognosis in Hepatocellular Carcinoma

By LabMedica International staff writers
Posted on 12 Oct 2020
Print article
Image: Photomicrograph of histopathology of hepatocellular carcinoma, the most common form of primary liver cancer, showing end-stage cirrhosis - blue collagen (fibrosis) Mallory bodies; loss of normal liver architecture; and nuclear atypia. (Photo courtesy of Nephron).
Image: Photomicrograph of histopathology of hepatocellular carcinoma, the most common form of primary liver cancer, showing end-stage cirrhosis - blue collagen (fibrosis) Mallory bodies; loss of normal liver architecture; and nuclear atypia. (Photo courtesy of Nephron).
Hepatocellular carcinoma (HCC) is an inflammation-related cancer, where non-resolving inflammation contributes to its development and progression. Peripheral inflammatory cells have been shown to be associated with the prognosis of various types of cancer.

Immune cells conduct their functions in the tumor microenvironment, and in the peripheral blood to promote metastasis The quantification of peripheral blood inflammatory cells such as neutrophils, lymphocytes, monocytes, and platelets, as well as their ratios, have been identified and validated as novel biomarkers with prognostic significance in several cancers.

A team of hepatologists at the Pusan National University School of Medicine (Yangsan, Republic of Korea) and their associate retrospectively analyzed 1,681 patients with HCC who were newly diagnosed between November 2008 and March 2018. Included in the study were 1,335 (79.4%) males and 346 (20.6%) females. The patients ranged in age from 27 to 88 years, and the median age was 60 years. Hepatitis B, hepatitis C, and alcoholic liver disease were diagnosed in 1,039 (61.8%), 279 (16.6%), and 184 (11.0%) patients, respectively. The frequency of patients with underlying liver cirrhosis was 85.1%.

All pretreatment routine blood cell examinations that were performed within two weeks before treatment were used for the analysis. Overall survival (OS) was calculated from the date of HCC diagnosis to the date of death or last follow-up. OS was compared for between patients with high and low neutrophils, lymphocytes, and monocytes (dichotomized by median values).

The scientist used univariate and multivariate analyses, and found that individual neutrophil, lymphocyte and monocyte cell counts were independent indicators of poor OS. High neutrophil (≥3100 × 106/L) and, monocyte (≥470 × 106/L) counts and low lymphocyte counts (< 1640 × 106/L) significantly associated with reduced OS. Neutrophil and, monocyte cell counts rose and lymphocyte counts decreased in association with advancing the Barcelona Clinic Liver Cancer stage.

The team also analyzed the combination score and found that higher neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lower lymphocyte to monocyte ratio (LMR) had worse OS. Patients with high neutrophils and monocytes were more likely to have larger tumor size. The presence of vascular invasion was associated with high neutrophil and, monocyte counts and with low lymphocyte counts. High neutrophils and monocyte counts were associated with extrahepatic metastasis.

The authors concluded that pretreatment peripheral neutrophils, lymphocytes, and monocytes are independently associated with outcomes of patients with HCC. These cells provide a noninvasive, low-cost, easy, and reproducible biomarker that can be used in routine clinical practice to predict the prognosis of patients with HCC. The study was published on September 29, 2020 in the journal BMC Cancer.

Related Links:
Pusan National University School of Medicine


Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.